Medication device with protein stabilizing surface coating
First Claim
1. A medical device comprising a surface having a polypropylene glycol/polyethylene glycol polymer covalently attached thereto, wherein the polypropylene glycol/polyethylene glycol polymer has a molecular weight of about 1800 Daltons and comprises a compound of the following general formula:
- and wherein the surface having the polypropylene glycol/polyethylene glycol polymer covalently attached thereto defines a surface contact angle less than about 45 degrees and exhibits an insulin adsorption profile of less than about 1.0 microgram per square centimeter.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides medical devices such as medication infusion pumps having internal surfaces that are treated to inhibit protein denaturation. In accordance with the invention, hydrophilic internal surfaces and related coating methods are provided to reduce or eliminate accumulation of medication deposits which can otherwise occur when handling complex protein-based medications. Preferred hydrophilic pump surfaces include hydrophilic surfactants (PEO) or (PEG) coatings which exhibit very low protein adsorption characteristics. Several methods are disclosed for producing such treated surfaces including the covalent attachment of hydrophilic surfactants.
-
Citations
20 Claims
-
1. A medical device comprising a surface having a polypropylene glycol/polyethylene glycol polymer covalently attached thereto, wherein the polypropylene glycol/polyethylene glycol polymer has a molecular weight of about 1800 Daltons and comprises a compound of the following general formula:
-
and wherein the surface having the polypropylene glycol/polyethylene glycol polymer covalently attached thereto defines a surface contact angle less than about 45 degrees and exhibits an insulin adsorption profile of less than about 1.0 microgram per square centimeter. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
-
11. A method of inhibiting the denaturation of insulin on a surface comprising covalently attaching to the surface a polypropylene glycol/polyethylene glycol polymer comprising the following general formula:
-
wherein the polypropylene glycol/polyethylene glycol polymer has a molecular weight of about 1800, and wherein the treatment produces a surface that defines a surface contact angle less than about 45 degrees and exhibits an insulin adsorption profile of less than about 1.0 microgram per square centimeter. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18)
-
-
19. A process for treating a surface to inhibit the denaturation of insulin on the surface comprising covalently attaching to the surface a polypropylene glycol/polyethylene glycol polymer comprising the following general formula:
-
wherein the polypropylene glycol/polyethylene glycol polymer has a molecular weight of about 1800, and wherein the process produces a surface that defines a surface contact angle less than about 45 degrees and exhibits an insulin adsorption profile of less than about 1.0 microgram per square centimeter. - View Dependent Claims (20)
-
Specification